Daiwa Capital Markets Lowers Abbott Laboratories (NYSE:ABT) Price Target to $113.00

Abbott Laboratories (NYSE:ABT) had its price objective cut by equities research analysts at Daiwa Capital Markets from $136.00 to $113.00 in a report released on Friday,MarketScreener reports. The firm presently has an “outperform” rating on the healthcare product maker’s stock. Daiwa Capital Markets’ price objective indicates a potential upside of 3.37% from the stock’s previous close.

A number of other analysts have also recently commented on ABT. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Benchmark assumed coverage on Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price objective for the company. Raymond James Financial dropped their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday. Finally, William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $138.40.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $109.31 on Friday. The company has a 50 day moving average price of $122.77 and a 200 day moving average price of $127.46. The firm has a market capitalization of $190.08 billion, a P/E ratio of 29.39, a PEG ratio of 1.69 and a beta of 0.72. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the business posted $1.34 EPS. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Institutional Trading of Abbott Laboratories

A number of hedge funds have recently added to or reduced their stakes in ABT. Charles Schwab Trust Co grew its holdings in shares of Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after buying an additional 15,394 shares in the last quarter. Asset Management One Co. Ltd. boosted its position in Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after acquiring an additional 19,966 shares during the last quarter. Nordea Investment Management AB grew its stake in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares in the last quarter. Seaview Investment Managers LLC acquired a new stake in Abbott Laboratories in the 2nd quarter valued at about $11,068,000. Finally, iA Global Asset Management Inc. lifted its stake in Abbott Laboratories by 94.0% in the 3rd quarter. iA Global Asset Management Inc. now owns 144,062 shares of the healthcare product maker’s stock worth $19,296,000 after purchasing an additional 69,803 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a portfolio reset tied to a deal with Exact Sciences that refocuses its cancer diagnostics strategy — investors appear to view the move as a strategic repositioning that could improve longer‑term growth in diagnostics. Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal
• Positive Sentiment: Freedom Capital upgraded ABT from “hold” to “strong‑buy,” a bullish vote that can attract buy‑side interest and support near‑term buying pressure. Freedom Capital upgrade (Zacks)
• Neutral Sentiment: Analyst commentary and feature pieces are framing Abbott as a steady, dividend‑oriented healthcare name, which reinforces income investor interest but is unlikely to drive a large repricing on its own. Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist
• Neutral Sentiment: Coverage pieces and analyst‑call writeups summarize Q4 takeaways and evolving price targets; useful for longer‑term positioning but largely reiterative. How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) 5 Insightful Analyst Questions From Abbott’s Q4 Call
• Neutral Sentiment: Updates projecting “decent organic sales growth” for 2026 support baseline expectations for revenue improvement but are not a catalyst by themselves. Decent organic sales growth expected for Abbott Laboratories (ABT) in 2026
• Negative Sentiment: Daiwa Capital Markets lowered its price target to $113 (from $136) while keeping an “outperform” call — a downward PT revision that can cool momentum and signals reduced near‑term upside expectations. Daiwa Securities adjusts Abbott PT to $113
• Negative Sentiment: Leerink Partners cut its target to $119 (from $136) and moved to “market perform,” another analyst downgrade that adds pressure and contributes to today’s mixed tone. Leerink Partners adjusts Abbott PT to $119 TickerReport coverage

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.